Wikidata entity: Q280786
C₁₉H₂₅N₅O₄ (P274)
Quantities
| P4250 | defined daily dose | 5 |
| P2067 | mass | 387.191 |
| P233 | canonical SMILES | String | COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC | ??? |
| P373 | Commons category | String | Terazosin | ??? |
| P366 | has use | ... | Q12140 (medication) | medication |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P8026 | LiverTox likelihood score | ... | Q83284667 (LiverTox toxicity likelihood category E) | LiverTox toxicity likelihood category E |
| P2175 | medical condition treated | ... | Q41861 (arterial hypertension) | arterial hypertension |
| P2175 | medical condition treated | ... | Q506659 (prostatic hypertrophy) | prostatic hypertrophy |
| P2175 | medical condition treated | ... | Q1366695 (urinary retention) | urinary retention |
| P2175 | medical condition treated | ... | Q32057211 (prostatic adenoma) | prostatic adenoma |
| P129 | physically interacts with | ... | Q4734884 (Adrenoceptor alpha 1A) | Adrenoceptor alpha 1A |
| P129 | physically interacts with | ... | Q4734886 (Adrenoceptor alpha 1B) | Adrenoceptor alpha 1B |
| P129 | physically interacts with | ... | Q4734887 (Adrenoceptor alpha 1D) | Adrenoceptor alpha 1D |
| P769 | significant drug interaction | ... | Q191521 (sildenafil) | sildenafil |
| P769 | significant drug interaction | ... | Q408556 (levobunolol) | levobunolol |
| P769 | significant drug interaction | ... | Q409468 ((RS)-metoprolol) | (RS)-metoprolol |
| P769 | significant drug interaction | ... | Q412534 (carvedilol) | carvedilol |
| P769 | significant drug interaction | ... | Q413591 (sotalol) | sotalol |
| P769 | significant drug interaction | ... | Q410291 (verapamil) | verapamil |
| P769 | significant drug interaction | ... | Q411325 (atenolol) | atenolol |
| P769 | significant drug interaction | ... | Q412515 (bisoprolol) | bisoprolol |
| P769 | significant drug interaction | ... | Q418101 (pindolol) | pindolol |
| P769 | significant drug interaction | ... | Q418130 (nebivolol) | nebivolol |
| P769 | significant drug interaction | ... | Q418857 (acebutolol) | acebutolol |
| P769 | significant drug interaction | ... | Q420586 (celiprolol) | celiprolol |
| P769 | significant drug interaction | ... | Q423364 (propranolol) | propranolol |
| P769 | significant drug interaction | ... | Q424156 (tadalafil) | tadalafil |
| P769 | significant drug interaction | ... | Q424161 (vardenafil) | vardenafil |
| P769 | significant drug interaction | ... | Q424952 (nadolol) | nadolol |
| P769 | significant drug interaction | ... | Q794162 (betaxolol) | betaxolol |
| P769 | significant drug interaction | ... | Q958087 (labetalol) | labetalol |
| P769 | significant drug interaction | ... | Q2873270 (avanafil) | avanafil |
| P279 | subclass of | ... | Q11173 (chemical compound) | chemical compound |
| P2868 | subject has role | ... | Q1927838 (alpha blocker) | alpha blocker |
| P2868 | subject has role | ... | Q50430371 (adrenergic alpha-1 receptor antagonists) | adrenergic alpha-1 receptor antagonists |
| P2868 | subject has role | ... | Q50430468 (urological agents) | urological agents |
| P2275 | World Health Organisation international non-proprietary name | Monolingualtext | terazosin | ??? |
Why not click here or view trends?
log id: 3055861